Dragging Ras Back in the Ring

Cited by (801)

Items 201–300 of 801

1. Machine Learning-Driven Multiscale Modeling: Bridging the Scales with a Next-Generation Simulation Infrastructure
   Helgi I. Ingólfsson, Harsh Bhatia, Fikret Aydin, Tomas Oppelstrup, César A. López, Liam G. Stanton, Timothy S. Carpenter, Sergio Wong, Francesco Di Natale, Xiaohua Zhang et al. · 2023 · Journal of Chemical Theory and Computation
2. Endometrial Carcinoma: Specific Targeted Pathways
   Núria Eritja, Andrée Yeramian, Bo‐Juen Chen, David Llobet‐Navàs, Eugenia Ortega, Eva Colás, Miguel Abal, Xavier Dolcet, Jaume Reventós, Xavier Matías‐Guiu · 2016 · Advances in experimental medicine and biology
3. Total Chemical Synthesis and Folding of All- l and All- d Variants of Oncogenic KRas(G12V)
   Adam M. Levinson, John H. McGee, Andrew G. Roberts, Gardner S. Creech, Ting Wang, Michael T. Peterson, Ronald C. Hendrickson, Gregory L. Verdine, Samuel J. Danishefsky · 2017 · Journal of the American Chemical Society
4. Malignant Transformation and Associated Biomarkers of Ovarian Endometriosis: A Narrative Review
   Л.М. Михалева, A.I. Davydov, Пацап Ольга Игоревна, Михайленко Елизавета Вячеславовна, Vladimir Nikolaevich Nikolenko, Маргарита Е. Неганова, Sergey G. Klochkov, Siva G. Somasundaram, Cecil E. Kirkland, Gjumrakch Aliev · 2020 · Advances in Therapy
5. AACR Cancer Progress Report 2015
   Jose M Baselga, Nina Bhardwaj, Lewis C. Cantley, Ronald P. DeMatteo, Raymond N. DuBois, Margaret Foti, Susan M. Gapstur, William C. Hahn, Lee J. Helman, Roy A. Jensen et al. · 2015 · Clinical Cancer Research
6. USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer
   Julia M. Fraile, Eusebio Manchado, Amaia Lujambio, Vı́ctor Quesada, Diana Campos-Iglesias, Thomas R. Webb, Scott W. Lowe, Carlos López-Otı́n, José M.P. Freije · 2017 · Journal of Biological Chemistry
7. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition
   Peter Dietrich, Silke Kuphal, Thilo Spruß, Claus Hellerbrand, Anja‐Katrin Bosserhoff · 2017 · Oncogene
8. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
   Zhiwei Liu, Yingluo Liu, Lili Qian, Shangwen Jiang, Xiameng Gai, Shu Ye, Yuehong Chen, Xiaomin Wang, Linhui Zhai, Jun Qiang Xu et al. · 2021 · Molecular Cell
9. Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells
   Lee, Wookjae, Lee, Joon Ho, Jun, Soyeong, Lee, Ji Hyun, Bang, Duhee · 2018 · Scientific Reports
10. Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
    Yuchun Niu, Anqi Lin, Peng Luo, Weiliang Zhu, Ting Wei, Ruixiang Tang, Linlang Guo, Jian Zhang · 2020 · Frontiers in Pharmacology
11. Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer
    Tao Guo, Xue Dong, Shanli Xie, Ling Zhang, Peibin Zeng, Lin Zhang · 2021 · Cancer Management and Research
12. Integrated multi-omics characterization of KRAS mutant colorectal cancer
    Wei Chong, Xingyu Zhu, Huicheng Ren, Chunshui Ye, Kang Xu, Zhe Wang, Shengtao Jia, Liang Shang, Leping Li, Hao Chen · 2022 · Theranostics
13. RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis
    Yu-Ting Huang, Meng Zhao, Haixu Xu, Ke Wang, Zheng Fu, Yuan Jiang, Zhi Yao · 2014 · Oncotarget
14. T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy
    Malcolm J. W. Sim, Peter D. Sun · 2022 · Frontiers in Immunology
15. Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers
    Nicole M. Baker, Hoi Yee Chow, Jonathan Chernoff, Channing J. Der · 2014 · Clinical Cancer Research
16. Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response
    Elda Grabocka, Cosimo Commisso, Dafna Bar‐Sagi · 2014 · Clinical Cancer Research
17. KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation
    Jia Lu, Asim K. Bera, Sudershan Reddy Gondi, Kenneth D. Westover · 2017 · Biochemistry
18. KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
    Saveri Bhattacharya, Mark A. Socinski, Timothy Francis Burns · 2015 · Clinical and Translational Medicine
19. Probing the Conformational and Energy Landscapes of KRAS Membrane Orientation
    Priyanka Prakash, Alemayehu Abebe Gorfe · 2019 · The Journal of Physical Chemistry B
20. Toward a More Precise Future for Oncology
    Murciano-Goroff, Yonina R., Taylor, Barry S., Hyman, David M., Schram, Alison M. · 2020 · Cancer Cell
21. The structural basis for cancer treatment decisions
    Ruth Nussinov, Hyunbum Jang, Chung‐Jung Tsai · 2014 · Oncotarget
22. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations
    Claudia Trojaniello, Lucia Festino, Vito Vanella, Paolo A. Ascierto · 2019 · Expert Review of Clinical Pharmacology
23. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer
    Niranjan Awasthi, David Kronenberger, Alexis Stefaniak, Sazzad Hassan, Urs W. von Holzen, Margaret A. Schwarz, Roderich Egbert Schwarz · 2019 · Cancer Letters
24. Conformational transformation of switch domains in GDP/K-Ras induced by G13 mutants: An investigation through Gaussian accelerated molecular dynamics simulations and principal component analysis
    Jianzhong Chen, Lifei Wang, Wei Wang, Haibo Sun, Laixue Pang, Huayin Bao · 2021 · Computers in Biology and Medicine
25. Pharmacological restoration of GTP hydrolysis by mutant RAS
    Antonio Cuevas-Navarro, Yasin Pourfarjam, Feng Hu, Diego J. Rodriguez, Alberto Vides, Ben Sang, Shijie Fan, Yehuda Goldgur, Elisa de Stanchina, Piro Lito · 2024 · Nature
26. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma
    Peter Dietrich, Anne Gaza, Laura Wormser, VALERIE K. FRITZ, Claus Hellerbrand, Anja‐Katrin Bosserhoff · 2019 · Neoplasia
27. Current Treatment of Juvenile Myelomonocytic Leukemia
    Christina Mayerhofer, Charlotte Marie Niemeyer, Christian Flotho · 2021 · Journal of Clinical Medicine
28. A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation
    Guowei Yin, Samantha Kistler, Samuel D. George, Nora Kuhlmann, Leslie A. Garvey, Minh V. Huynh, Rachel Bagni, Michael Lammers, Channing J. Der, Sharon L. Campbell · 2017 · Journal of Biological Chemistry
29. A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia
    Nagore I. Marín‐Ramos, Moisés Balabasquer, Francisco J. Ortega-Nogales, Iván R. Torrecillas, Ana Gil-Ordóñez, Beatriz Marcos‐Ramiro, Pedro Aguilar-Garrido, Ian Cushman, Antonio Romero, Francisco J. Medrano et al. · 2019 · Journal of Medicinal Chemistry
30. Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice
    Huazhen Qin, Yu Jiang, Jian Zhang, Chao Deng, Zhiyuan Zhong · 2019 · Molecular Pharmaceutics
31. KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin
    Wen-Hsuan Chang, Thuy‐Tien T. Nguyen, Chia‐Hsin Hsu, Kirsten L. Bryant, Hong Jin Kim, Haoqiang Ying, Jon W. Erickson, Channing J. Der, Richard A. Cerione, Marc A. Antonyak · 2021 · Cancer Letters
32. BCL6 confers KRAS-mutant non–small-cell lung cancer resistance to BET inhibitors
    Jiawei Guo, Yanan Liu, Jing Lv, Bin Zou, Zhi Chen, Kun Li, Juanjuan Feng, Zhenyu Cai, Lai Wei, Mingyao Liu et al. · 2021 · Journal of Clinical Investigation
33. Targeting KRAS mutant lung cancer: light at the end of the tunnel
    Matthias Drosten, Mariano Barbacid · 2021 · Molecular Oncology
34. Engineering therapeutic proteins for cell entry: the natural approach
    Sandrine Guillard, Ralph Minter, Ronald H. Jackson · 2015 · Trends in biotechnology
35. Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer
    Junli Guo, Keping Xie, Shaojiang Zheng · 2016 · International Journal of Biological Sciences
36. Studying protein–protein interactions: progress, pitfalls and solutions
    Sheri L. Hayes, Beatrice Malacrida, Maeve Bailey‐Whyte, Patrick A. Kiely · 2016 · Biochemical Society Transactions
37. Mutated RAS: Targeting the “Untargetable” with T Cells
    Praveen D. Chatani, James Chih‐Hsin Yang · 2019 · Clinical Cancer Research
38. Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape
    Behnam Nabet, Pilib Ó Broin, Jaime M. Reyes, Kevin R. Shieh, Charles Y. Lin, Christine Will, Relja Popovic, Teresa Ezponda, James E. Bradner, Aaron A. Golden et al. · 2015 · Cell Reports
39. RAC1 and Melanoma
    Ruth Halaban · 2014 · Clinical Therapeutics
40. KRAS Engages AGO2 to Enhance Cellular Transformation
    Sunita Shankar, Sethuramasundaram Pitchiaya, Rohit Malik, Vishal Kothari, Yasuyuki Hosono, Anastasia K. Yocum, Harika Gundlapalli, Yasmine N. White, Ari J. Firestone, Xuhong Cao et al. · 2016 · Cell Reports
41. Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms
    H Y Lau, Jingyi Tang, Patrick J. Casey, Mei Wang · 2017 · Oncogene
42. Blocking Ras inhibition as an antitumor strategy
    Nagore I. Marín‐Ramos, Silvia Ortega‐Gutiérrez, María Luz López-Rodríguez · 2018 · Seminars in Cancer Biology
43. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer
    Yeo Wool Kang, Ji Eun Lee, Kyung Hee Jung, Mi Kwon Son, Seungmin Shin, Soo‐Jeong Kim, Zhenghuan Fang, HONG HUA YAN, Jung Hee Park, Boreum Han et al. · 2018 · Cancer Letters
44. RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications
    Omer Abdelaziz Mohammed Saeed, Antonio Lopez-beltran B, Kurt W. Fisher, Marina Scarpelli, Rodolfo Montironi, Alessia Cimadamore, Francesco Massari, Matteo Santoni, Liang Cheng C · 2018 · Journal of Clinical Pathology
45. Nootkatone, an AMPK activator derived from grapefruit, inhibits KRAS downstream pathway and sensitizes non-small-cell lung cancer A549 cells to adriamycin
    Le Van Manh Hung, Jeong Yong Moon, Jiyeon Ryu, Somi Kim Cho · 2019 · Phytomedicine
46. The Methods Employed in Mass Spectrometric Analysis of Posttranslational Modifications (PTMs) and Protein–Protein Interactions (PPIs)
    Rama Yakubu, Edward Nieves, Louis M. Weiss · 2019 · Advances in experimental medicine and biology
47. An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development
    Sunita Shankar, Jean Ching-Yi Tien, Ronald F. Siebenaler, Seema Chugh, Vijaya L. Dommeti, Sylvia Zelenka-Wang, Jessica J. Waninger, Kristin M. Juckette, Alice Xu, Xiao-Ming Wang et al. · 2020 · Nature Communications
48. Allelic Ratio of KRAS Mutations in Pancreatic Cancer
    Jochen K. Lennerz, Albrecht Stenzinger · 2015 · The Oncologist
49. Induction of early growth response gene 1 (EGR1) by endoplasmic reticulum stress is mediated by the extracellular regulated kinase (ERK) arm of the MAPK pathways
    Jixiu Shan, Elizabeth E. Dudenhausen, Michael S. Kilberg · 2018 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
50. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
    Heng‐Chung Kung, Jun Yu · 2023 · MedComm
51. Non-canonical integrin signaling activates EGFR and RAS-MAPK-ERK signaling in small cell lung cancer
    Karla Rubio, Addi J. Romero‐Olmedo, Pouya Sarvari, Guruprasadh Swaminathan, Vikas Ranvir, Diana G. Rogel-Ayala, Julio Cordero, Stefan Günther, Aditi Mehta, Birgit Bassaly et al. · 2023 · Theranostics
52. Intrinsic K-Ras dynamics: A novel molecular dynamics data analysis method shows causality between residue pair motions
    Sezen Vatansever, Zeynep Hulya Gumus, Burak Erman · 2016 · Scientific Reports
53. The role of KRAS splice variants in cancer biology
    Cristina Nuevo‐Tapioles, Mark R. Philips · 2022 · Frontiers in Cell and Developmental Biology
54. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
    Wenlin Shao, Yuji M. Mishina, Yunjiang Feng, Giordano Caponigro, Vesselina G. Cooke, Stacy Rivera, Yingyun Wang, Fang Shen, Joshua M. Korn, Lesley A. Mathews Griner et al. · 2018 · Cancer Research
55. Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities
    Marcus R. Kelly, Kaja Kostyrko, Kyuho Han, Nancie A. Mooney, Edwin E. Jeng, Kaitlyn Spees, Phuong Dinh, Keene L. Abbott, Dana M. Gwinn, Alejandro Sweet-Cordero et al. · 2020 · Cancer Discovery
56. Efforts to Develop KRAS Inhibitors
    Holderfield, Matthew · 2018 · Cold Spring Harbor Perspectives in Medicine
57. K-RAS mutations indicating primary resistance to crizotinib in ALK -rearranged adenocarcinomas of the lung: Report of two cases and review of the literature
    Maria Cecilia Mengoli, Fausto Barbieri, Federica Bertolini, Marcello Tiseo, Giulio Rossi · 2016 · Lung Cancer
58. Structural fingerprints, interactions, and signaling networks of RAS family proteins beyond RAS isoforms
    Saeideh Nakhaei‐Rad, Fereshteh Haghighi, Parivash Nouri, Soheila Rezaei Adariani, Jana Lissy, Neda S. Kazemein Jasemi, Radovan Dvorský, Mohammad Reza Ahmadian · 2018 · Critical Reviews in Biochemistry and Molecular Biology
59. PIP2 Influences the Conformational Dynamics of Membrane-Bound KRAS4b
    Mark A. McLean, Andrew G. Stephen, Stephen G. Sligar · 2019 · Biochemistry
60. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer
    Sandro Mascena Gomes-Filho, Edmilson Ozorio dos Santos, Ester Risério Matos Bertoldi, Luiza Coimbra Scalabrini, Vitor Heidrich, Bianca Dazzani, Elena Levantini, Eduardo M. R. Reis, Daniela S. Daniela Sanchez Bassères · 2020 · Cellular Oncology
61. Targeting mutated GTPase KRAS in tumor therapies
    Guangjin Fan, Linlin Lou, Zhendong Song, Xiaolei Zhang, Xiao‐Feng Xiong · 2021 · European Journal of Medicinal Chemistry
62. The role of wild-type RAS in oncogenic RAS transformation
    Sheffels, Erin, Kortum, Robert L. · 2021 · Genes
63. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
    Irene Ischenko, Oleksi Petrenko, Michael J. Hayman · 2015 · Oncotarget
64. SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status
    Ha Yong Song, Marco Biancucci, Hong-Jun Kang, Carol O'Callaghan, Seong‐Hoon Park, Daniel R. Principe, Haiyan Jiang, Yufan Yan, K.J.F. Satchell, Kirtee Raparia et al. · 2016 · Oncotarget
65. In-silico design of peptide inhibitors of K-Ras target in cancer disease
    Mehreen Ghufran, Ashfaq Ur Rehman, Masaud Shah, Muhammad Ayaz, Ho Leung Ng, Abdul Wadood · 2019 · Journal of Biomolecular Structure and Dynamics
66. Small molecular inhibitors for KRAS-mutant cancers
    Xuan Wu, Wenping Song, Cheng Cheng, Ziyang Liu, Xiang Li, Yu Cui, Yao Gao, Li Ding · 2023 · Frontiers in Immunology
67. The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan
    Lisonia Gkioni, Tobias Nespital, Maarouf Baghdadi, Carolina Monzó, Jitin Bali, Taim Nassr, Anna Lena Cremer, Andreas Beyer, Joris Deelen, Heiko Backes et al. · 2025 · Nature Aging
68. Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update
    Robert Jr. Roskoski · 2026 · Pharmacological Research
69. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites
    Robert J. Allaway, Dawn A. Fischer, Francine Blumental De Abreu, Timothy B. Gardner, Stuart R. Gordon, Richard J. Barth, Thomas A. Colacchio, Matthew D. Wood, Balint Z Kacsoh, Stephanie J. Bouley et al. · 2016 · Oncotarget
70. How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
    Ethan J. Brock, Kyungmin Ji, John J. Reiners, Raymond R. Mattingly · 2015 · Mini-Reviews in Medicinal Chemistry
71. Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras
    Chris J. Novotny, Gregory L. Hamilton, Frank P. McCormick, Kevan M. Shokat · 2017 · ACS Chemical Biology
72. IκB Kinase α Is Required for Development and Progression of KRAS -Mutant Lung Adenocarcinoma
    Malamati Vreka, Ioannis Lilis, Maria Papageorgopoulou, Georgia A. Giotopoulou, Marina Lianou, Ioanna Giopanou, Nikolaos I. Kanellakis, Μάγδα Σπέλλα, Theodora Agalioti, Vasileios Armenis et al. · 2018 · Cancer Research
73. Identification of a new inhibitor of KRAS‐PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer
    Leung, Elaine Lai‐Han, Luo, Lian Xiang, Li, Ying, Liu, Zhong‐Qiu, Li, Lan Lan, Shi, Dan Feng, Xie, Ying, Huang, Min, Lu, Lin Lin, Duan, Fu Gang et al. · 2019 · International Journal of Cancer
74. Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells
    Nathaniel Edward Bennett Saidu, Marie Bretagne, Audrey Mansuet‐Lupo, Pierre‐Alexandre Just, Karen Leroy, Olivier Cerles, Sandrine Chouzenoux, Carole Nicco, Diane Damotte, Marco Alifano et al. · 2018 · Oncotarget
75. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
    Karmele Valencia, Oihane Erice, Kaja Kostyrko, Simone Hausmann, Elizabeth Guruceaga, Anuradha Tathireddy, Natasha Mahealani Flores, Leanne C. Sayles, Alex Gia Lee, Rita Fragoso et al. · 2019 · Journal of Clinical Investigation
76. Paradoxical effects of statins on endothelial and cancer cells: the impact of concentrations
    Yasin Ahmadi, Javad Khalili Fard, Dlzar Dlshad Ghafoor, Ali Hussein Eid, Amirhossein Sahebkar · 2023 · Cancer Cell International
77. MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer
    Eduard Stefan, Klaus Bister · 2017 · Current topics in microbiology and immunology
78. PP6 Disruption Synergizes with Oncogenic Ras to Promote JNK-Dependent Tumor Growth and Invasion
    Xianjue Ma, Jinyu Lu, Yongli Dong, Daming Li, Juan Nicolas Malagón, Tian Xu · 2017 · Cell Reports
79. Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer
    Iwao Shimomura, Akira Yokoi, Isaku Kohama, Minami Kumazaki, Yuji Tada, Koichiro Tatsumi, Takahiro Ochiya, Yusuke Yamamoto · 2019 · Cancer Letters
80. The prevalence and prognostic value of KRAS co‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients
    Dongjing Cai, Chengping Hu, Li Li, S. Deng, Jing Yang, Han Han‐Zhang, Min Li · 2019 · Cancer Medicine
81. Intrinsic GTPase activity of K-RAS monitored by native mass spectrometry
    Moghadamchargari, Zahra, Huddleston, Jamison, Shirzadeh, Mehdi, Zheng, Xueyun, Clemmer, David E., M. Raushel, Frank, Russell, David H., Laganowsky, Arthur · 2019 · Biochemistry
82. Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants
    Moghadamchargari, Zahra, Shirzadeh, Mehdi, Liu, Chang, Schrecke, Samantha, Packianathan, Charles, Russell, David H., Zhao, Minglei, Laganowsky, Arthur · 2021 · Proceedings of the National Academy of Sciences
83. Parameterization of Palmitoylated Cysteine, Farnesylated Cysteine, Geranylgeranylated Cysteine, and Myristoylated Glycine for the Martini Force Field
    Yoav Atsmon‐Raz, D. Peter Tieleman · 2017 · The Journal of Physical Chemistry B
84. Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3
    Takahiro Nakagomi, Taichiro Goto, Yosuke Hirotsu, Daichi Shikata, Yujiro Yokoyama, Rumi Higuchi, Sotaro Otake, Kenji Amemiya, Toshio Oyama, Hitoshi Mochizuki et al. · 2018 · Cancers
85. Differential Outcomes in Codon 12/13 and Codon 61 NRAS -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS -Mutated Tumors
    James M. Cleary, Victoria Wang, Rebecca Suk Heist, Scott Kopetz, Edith Peterson Mitchell, James A. Zwiebel, Kevin S. Kapner, Helen X. Chen, Shuli Li, Robert J. Gray et al. · 2021 · Clinical Cancer Research
86. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS
    Robert Jr. Roskoski · 2021 · Pharmacological Research
87. ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL
    Yulin Wang, Gefei Guan, Wen Cheng, Yang Jiang, Fengping Shan, Anhua Wu, Peng Cheng, Zongze Guo · 2018 · BMC Cancer
88. Functional link between plasma membrane spatiotemporal dynamics, cancer biology, and dietary membrane-altering agents
    Alfredo Erazo‐Oliveras, Natividad Roberto Fuentes, Rachel C. Wright, Robert S. Chapkin · 2018 · Cancer and Metastasis Reviews
89. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation
    Kai Wang, Graham S. Baldwin, Mehrdad Nikfarjam, Hong Zhen He · 2018 · World Journal of Gastroenterology
90. Approaches to inhibiting oncogenic K-Ras
    Alemayehu Abebe Gorfe, Kwang‐Jin Cho · 2019 · Small GTPases
91. Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
    Lindor Qunaj, Michael S. May, Alfred I. Neugut, Benjamin O. Herzberg · 2023 · Frontiers in Oncology
92. Mutational Analysis of Ionizing Radiation Induced Neoplasms
    Amy L. Sherborne, Philip R. Davidson, Katharine Yu, Alice Nakamura, Mamunur Rashid, Jean L. Nakamura · 2015 · Cell Reports
93. AMPK Promotes Aberrant PGC1β Expression To Support Human Colon Tumor Cell Survival
    Kurt W. Fisher, Binita Das, Hyun Seok Kim, Beth K. Neilsen, Drew Gehring, Deandra R. Smith, Diane L. Costanzo-Garvey, Mario R. Fernandez, Michael G. Brattain, David L. Kelly et al. · 2015 · Molecular and Cellular Biology
94. EGFR phosphorylates FAM129B to promote Ras activation
    Haitao Ji, Jong-Ho Lee, Yugang Wang, Yilin Pang, Tao Zhang, Yan Xia, Lianjin Zhong, Jianxin Lyu, Zhimin Lu · 2015 · Proceedings of the National Academy of Sciences
95. NRAS destines tumor cells to the lungs
    Anastasios D. Giannou, Antonia Marazioti, Nikolaos I. Kanellakis, Ioanna Giopanou, Ioannis Lilis, Dimitra E. Zazara, Giannoula Ntaliarda, Danai Kati, Vasileios Armenis, Georgia A. Giotopoulou et al. · 2017 · EMBO Molecular Medicine
96. Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion
    Antonia Marazioti, Ioannis Lilis, Malamati Vreka, Hara Apostolopoulou, Argyro Kalogeropoulou, Ioanna Giopanou, Georgia A. Giotopoulou, Anthi C. Krontira, Marianthi P. Iliopoulou, Nikolaos I. Kanellakis et al. · 2018 · Nature Communications
97. Analysis of the miRNA Expression Profiles in the Zearalenone-Exposed TM3 Leydig Cell Line
    Mingyang Wang, Weiwei Wu, Lin Li, Jianbin He, Sheng Huang, Si Chen, Jia Chen, Miao Long, Shuhua Yang, Peng Li · 2019 · International Journal of Molecular Sciences
98. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option
    Peter Dietrich, K Freese, Abdo Mahli, Wolfgang Erwin Thasler, Claus Hellerbrand, Anja‐Katrin Bosserhoff · 2017 · Oncotarget
99. Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production
    Kartini Bte Iskandar, Majidah Rezlan, Sanjiv Kumar Yadav, Chuan Han Jonathan Foo, Gautam Sethi, Qiang Yu, Gregory Lucien Bellot, Shazib Pervaiz · 2015 · Antioxidants and Redox Signaling
100. Regulation of large and small G proteins by ubiquitination
     Henrik Gunnar Dohlman, Sharon L. Campbell · 2019 · Journal of Biological Chemistry